Boehringer Ingelheim partners with NCD Alliance to target Non-Communicable Diseases in underserved communities
27 sept. 2024 06h05 HE
|
Boehringer Ingelheim
Boehringer Ingelheim has entered a partnership with the NCD Alliance, a network dedicated to shaping a world in which everyone can live a healthy and productive life, free from the preventable...
Sandoz completes acquisition of leading antifungal agent Mycamine® from Astellas, reinforcing leading global anti-infectives portfolio
28 août 2023 01h15 HE
|
Novartis Pharma AG
Sandoz completes acquisition of worldwide brand rights for Mycamine® (micafungin sodium) from Astellas Leading global echinocandin, one of three major antifungal classes, will significantly...
Sandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis
25 août 2023 01h15 HE
|
Novartis Pharma AG
Biosimilar Tyruko® approved for all indications of reference medicine, with same dosing and administration schedule Sandoz continues to expand access to much-needed medications for patients...
Novartis publie l’invitation à l’AGE et la brochure d’information aux actionnaires. Sandoz publie le prospectus de cotation avant le vote sur la proposition de scission
18 août 2023 01h25 HE
|
Novartis Pharma AG
Annonce ad hoc en vertu de l’art. 53 LR Invitation à l’assemblée générale extraordinaire de Novartis du 15 septembre 2023 et publication d’une brochure d’information destinée aux...
Novartis publiziert Einladung und Aktionärsbroschüre zur ausserordentlichen Generalversammlung. Sandoz veröffentlicht den Kotierungsprospekt im Vorfeld der Abstimmung zum vorgeschlagenen Spin-off
18 août 2023 01h25 HE
|
Novartis Pharma AG
Ad-hoc-Meldung nach Art. 53 LR Einladung zur ausserordentlichen Generalversammlung von Novartis am 15. September 2023 und Informationsbroschüre für Aktionärinnen und Aktionäre publiziertSandoz...
Novartis issues EGM Invitation and Shareholder Information Brochure. Sandoz publishes Listing Prospectus ahead of proposed Spin-off vote
18 août 2023 01h25 HE
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Invitation to Novartis Extraordinary General Meeting on September 15, 2023, and Shareholder Information Brochure issuedSandoz Listing Prospectus...
Sandoz announces plans to build a Biosimilar Technical Development Center in Slovenia to support future growth of biosimilar pipeline
20 juil. 2023 01h15 HE
|
Novartis Pharma AG
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026New end-to-end drug substance and drug...
Sandoz introduces Act4Biosimilars Action Plan to accelerate patient access to biosimilar medicines
15 juin 2023 01h15 HE
|
Novartis Pharma AG
Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic...
Sandoz presents compelling investment proposition as standalone company at Capital Markets Day
08 juin 2023 01h15 HE
|
Novartis Pharma AG
Sandoz well positioned to deliver continued mid-single digit sales growth; core EBITDA margin of 24-26% and Free Cash Flow to more than double over mid term European champion committed to further...
Sandoz strengthens pipeline expansion through partnership to develop and manufacture multiple biosimilars
09 mai 2023 15h00 HE
|
Novartis Pharma AG
Sandoz and Just - Evotec Biologics announce partnership to develop and manufacture multiple biosimilars with an option for expansion Sandoz gains access to proprietary AI-driven technology platform...